Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Contact

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
options
options_strategies
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Kura Oncology (KURA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Notes

Alerts

Watch

Help

Kura Oncology and Kyowa Kirin Announce Strategic Collaboration for Ziftomenib Development with $330 Million Upfront Payment Quiver Quantitative, Inc. - Thu Nov 21, 2:24AM CST

Kura and Kyowa Kirin collaborate to develop ziftomenib for AML, providing substantial milestone payments and joint commercialization efforts.Quiver AI SummaryKura Oncology and Kyowa Kirin have announced...

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias Newswire.ca - Wed Nov 20, 4:00PM CST

– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and...

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias GlobeNewswire - Wed Nov 20, 4:00PM CST

Kura Oncology: Q3 Earnings Snapshot AP - Thu Nov 7, 4:15PM CST

Kura Oncology: Q3 Earnings Snapshot

Kura Oncology Reports Third Quarter 2024 Financial Results GlobeNewswire - Thu Nov 7, 3:05PM CST

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting GlobeNewswire - Tue Nov 5, 8:09AM CST

Kura Oncology to Report Third Quarter 2024 Financial Results GlobeNewswire - Thu Oct 31, 6:30AM CDT

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST) GlobeNewswire - Thu Oct 24, 6:30AM CDT

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors GlobeNewswire - Wed Oct 23, 6:30AM CDT

Kura Oncology: Q2 Earnings Snapshot AP - Thu Aug 8, 3:44PM CDT

Kura Oncology: Q2 Earnings Snapshot